We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials
Effectiveness and safety of oral semaglutide for type 2 diabetes in Chinese patients, analyzed by starting health factors
AI simplified
Abstract
Oral semaglutide led to greater reductions in HbA1c and body weight in 1,474 Chinese participants with type 2 diabetes.
- Greater reductions in HbA1c were noted in subgroups with higher baseline HbA1c levels.
- Similar baseline characteristics were observed across subgroups in both PIONEER trials.
- Most adverse events reported were gastrointestinal-related and classified as mild-to-moderate.
- The findings may support the efficacy and safety of oral semaglutide in diverse subpopulations with type 2 diabetes.
AI simplified
Key numbers
1474
Participants Evaluated
390 from PIONEER 11 and 1084 from PIONEER 12
p <0.05
Change in HbA Reduction
Significant difference observed for change in HbA by baseline HbA subgroups
≤10%
Adverse Events Incidence
Serious AEs in ≤10% of participants in PIONEER 11